OmniAb, Inc.
1.4700-0.08 (-5.16%)
Oct 29, 4:00:01 PM EDT · NasdaqGM · OABI · USD
Key Stats
Market Cap
211.61MP/E (TTM)
-Basic EPS (TTM)
-0.61Dividend Yield
0%Recent Filings
8-K
OmniAb's $30M private placement
OmniAb entered a securities purchase agreement on August 24, 2025, for a private placement of 21,254,106 common shares at $1.40 each—$1.85 for insiders—yielding $30 million in gross proceeds before fees. The deal closes August 26, funding working capital and corporate needs amid biotech pressures. New and existing investors joined, with Leerink Partners as agent. Yet closing hinges on conditions.
10-Q
Q2 FY2025 results
OmniAb's Q2 revenue fell 49% y/y to $3.9M, driven by lower milestones and service fees from a discontinued ion channel program, yet costs dropped 16% to $20.1M on reduced R&D headcount and external spend, narrowing the operating loss to $16.2M from $16.3M. YTD revenue declined 29% to $8.1M while expenses fell 14%, yielding a $35.1M operating loss versus $38.9M last year; net loss widened to $34.1M from $32.6M due to a smaller tax benefit, with diluted EPS of $(0.32) matching shares at 105.9M. Cash burn eased to $21.0M from operating activities, bolstered by a $3.0M gain from selling a Kv7.2 asset to Angelini in May. Liquidity stands solid at $41.6M in cash and equivalents plus short-term investments, with no debt. Partners hit 100 with 381 programs, including 32 in clinic. Regulatory pricing caps pose a balanced risk to partner royalties.
8-K
Q2 revenue dips but partners grow
OmniAb reported Q2 2025 revenue of $3.9 million, down from $7.6 million in 2024 due to lower milestone and service income, yet offset by $0.6 million from xPloration sales. The company added six new partners, hitting 100 active ones with 381 programs, and sold a small molecule program to Angelini Pharma for $3 million upfront plus over $170 million in milestones. Cash burn stayed low at $2.0 million. OmniAb affirms 2025 revenue guidance of $20-25 million.
8-K
Shareholders elect directors, ratify auditors
OmniAb shareholders elected Carolyn R. Bertozzi and John Higgins as Class III directors at the June 17, 2025 Annual Meeting, with Bertozzi facing significant withheld votes at 31 million shares. They ratified Ernst & Young as auditors for 2025 with overwhelming support, 84 million for versus just 110,000 against. Governance holds steady.
10-Q
Q1 FY2025 results
OmniAb's Q1 revenue climbed 9% year-over-year to $4.2M, fueled by a $1.0M phase 1 milestone and stronger license fees, though service revenue dipped 30% from discontinued ion channel programs. Operating loss narrowed to $18.8M from $22.6M, thanks to 13% lower R&D spend on reduced share-based comp and external costs, while net loss eased 4% to $18.2M or $0.17 per diluted share on 105.6M shares. Cash burn slowed, with operating cash use at $15.9M versus $17.0M last year; quarter-end cash and equivalents stood at $10.9M, short-term investments at $32.7M, and no debt. Active partners hit 95 with 378 programs, including 33 in clinic. Yet competition in antibody discovery tech remains fierce.
ABCL
AbCellera Biologics Inc.
5.62-0.01
ABP
Abpro Holdings, Inc
0.20-0.00
ABSI
Absci Corporation
4.37-0.03
IBIO
iBio, Inc.
1.54+0.15
ORKA
Oruka Therapeutics, Inc.
27.61+0.17
OVID
Ovid Therapeutics Inc.
1.45-0.04
SABS
SAB Biotherapeutics, Inc.
3.00-0.03
SCNI
Scinai Immunotherapeutics Ltd.
1.45-0.05
XBIT
XBiotech Inc.
2.37+0.00
ZURA
Zura Bio Limited
3.78+0.01